Clinical TrialJun 29, 2026, 07:00 AM
Biogen to Present New Alzheimer's Data at AAIC 2026
AI Summary
Biogen announced it will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference (AAIC) 2026. Key presentations will include clinical, biomarker, and safety results from the Phase 2 CELIA study for diranersen, an investigational tau-targeting ASO, which is advancing towards Phase 3 development. Additionally, new data on LEQEMBI (lecanemab) will be presented, focusing on subcutaneous administration, real-world use, and three-year LEADER study results. The company emphasized its continued commitment to innovation in Alzheimer's care.
Key Highlights
- Biogen to present new data on diranersen and lecanemab at AAIC 2026.
- Diranersen Phase 2 CELIA data will include clinical, biomarker, and safety results.
- Lecanemab presentations will highlight subcutaneous administration and real-world use.
- New analyses from the three-year LEADER study for lecanemab will be featured.
- Diranersen, a tau-targeting ASO, is advancing toward Phase 3 development.
- Diranersen received FDA Fast Track designation in 2025.
Price Impact
More from BIIB